2021年11月6日 · Poly ADP-ribose polymerase inhibitors (PARPi) have transformed ovarian cancer (OC) treatment, primarily for tumours deficient in homologous recombination repair. Combining VEGF-signalling inhibitors with PARPi has enhanced clinical benefit in OC.

2023年2月20日 · We investigated whether PARP/TRPM2 plays a role in VEGFi‐induced vascular dysfunction and whether PARP inhibition ameliorates the vasculopathy associated with VEGF inhibition. Human vascular smooth muscle cells (VSMCs), human aortic endothelial cells, and wild‐type mouse mesenteric arteries were studied.

2024年10月22日 · The insight into the role of VEGF and cytokine signaling in controlling hypoxia cycles, as well as the predictive assessment of the therapeutic effects of PARP inhibitors, represents a...

在临床前及早期临床研究中发现聚腺苷二磷酸核糖聚合酶 (PARP)抑制剂就是这类药物，可与免疫治疗起到相互协同的作用。 通过抑制DNA修复产生DNA损伤，增加肿瘤突变负荷，成为更具识别性的免疫治疗靶点。 《TherapeuticPotential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors》刊登于Frontiers in Oncology肿瘤学前沿杂志中， 详述阐明了PARP抑制和免疫联合治疗在改善实体肿瘤患者预后方面的前景，总结早期研究成果并展望进行中的研究，下面就由 …

2020年5月30日 · The data presented in this manuscript suggest that PARP-16 catalysis the priming mono ADP-ribosylation of VEGF which is a prerequisite for poly ADP-ribosylation of VEGF by TNKS-2. Angiogenesis, the formation of new blood vessels from the preexisting ones play a major role in regulating many physiological and pathological conditions.

2020年5月，美国食品药品监督管理局（Food and Drug Administration, FDA）批准PARP抑制剂奥拉帕利与抗血管生成抑制剂贝伐珠单抗联合，用于同源重组缺陷（HRD）阳性晚期卵巢癌的一线维持治疗[1]。

Underlying molecular mechanisms are unclear, but PARP-regulated transient receptor potential cation channel, subfamily M, member 2 (TRPM2), a redox-sensitive calcium channel, may be important. We investigated whether PARP/TRPM2 plays a role in VEGFi-induced vascular dysfunction and whether PARP inhibition ameliorates the vasculopathy associated ...

In the present study, we investigated a combination approach of bevacizumab + olaparib in KRAS-mut CRC in a preclinical setting. The combined therapy effectively prevented tumor growth in a KRAS-mut cancer cell-derived xenograft model, although this effect was not observed in vitro.

2021年11月6日 · Poly ADP-ribose polymerase inhibitors (PARPi) have transformed ovarian cancer (OC) treatment, primarily for tumours deficient in homologous recombination repair. Combining VEGF-signalling inhibitors with PARPi has enhanced clinical benefit in OC. To study drivers of efficacy when combining PARP inhi …

2020年9月1日 · In the present study, we investigated a combination approach of bevacizumab + olaparib in KRAS-mut CRC in a preclinical setting. The combined therapy effectively prevented tumor growth in a KRAS-mut cancer cell-derived xenograft model, although this effect was not observed in vitro.